Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T16:57:03.510Z.
Calculation as of: 2026-10-06T16:57:03.510Z.
Quote observation: 2026-10-06T16:55:21.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 934548bd97ab8c390298f716fcf622fc2d1107cfab085c47b2b47650fd31fbc6
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$668.53M
Price/OCF Ratio
14.49
TTM Avg
11.83
3Y Avg
25.95
5Y Avg
25.95
Market Cap
$666.57M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$660.39M
Price/OCF Ratio
2013.38
TTM Avg
1890.32
3Y Avg
1890.32
5Y Avg
1890.32
Market Cap
$688.89M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$702.71M
Price/OCF Ratio
N/A
TTM Avg
1184.35
3Y Avg
1178.25
5Y Avg
1178.25
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Helus Pharma Inc. (HELP) | $673.46M | N/A | N/A | N/A | N/A |
| Annexon, Inc. (ANNX)vs › | $674.21M | N/A | N/A | N/A | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $668.53M | 14.49 | 11.83 | 25.95 | 25.95 |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $666.57M | N/A | N/A | N/A | N/A |
| Solid Biosciences Inc. (SLDB)vs › | $681.76M | N/A | N/A | N/A | N/A |
| Starling Oncology, Inc. (STLN)vs › | $660.39M | 2013.38 | 1890.32 | 1890.32 | 1890.32 |
| Anteris Technologies Global Corp. (AVR)vs › | $688.89M | N/A | N/A | N/A | N/A |
| OmniAb, Inc. (OABI)vs › | $649.48M | N/A | 72.20 | 236.60 | 236.60 |
| Avalo Therapeutics, Inc. (AVTX)vs › | $702.71M | N/A | 1184.35 | 1178.25 | 1178.25 |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $707.08M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
